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Nutritional treatment improves the effectiveness  
of anti-cancer therapy
Michał Jankowski
Cancer disease is a growing health problem in today’s world. 
Malnutrition frequently occurs in cancer patients and is associated with their higher mortality rates. 
Nutritional interventions are recommended whenever clinically required and at every stage of oncological therapy. 
This allows prevention or treatment of cancer therapy-related complications thereby improving the effectiveness 
of such therapy, reducing cost, improving the quality of life, and prolonging the survival of some patients. From an 
overall perspective, adequate nutrition is necessary to ensure the most favourable outcomes of oncological therapy.
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Introduction
Cancer is a growing problem in today’s world with more 
than 14 million sufferers estimated for 2017 [1]. The highly 
developed countries of the West bear the highest risk, ne-
vertheless anti-cancer treatment in these countries is the 
most effective [2]. Such cures mostly depend on applying 
appropriate local treatment methods: surgery and radio-
therapy, supplemented by systemic treatment. Quoting 
Professor Tadeusz Koszarowski, ‘cancer treatment forms part 
of an integrated therapy including surgery and coordina-
ted in its broadest sense with radiotherapy, chemotherapy 
and endocrine-therapy’. Nowadays, the role of nutritional 
intervention is also a prerequisite. 
Cancer patients malnutrition
Malnutrition in cancer patients is multifactorial, arising 
both from insufficient nutrients supplied as well their incre-
ased loss because of the increased demand during cancer 
development and the presence of other accompanying 
diseases. Malnutrition is associated with elevated mortality 
rates in cancer patients; as is likewise the case with other 
diseases, for example in cardiovascular disease [3].
An inadequate supply of nutrients is a very common 
occurrence in oncological patients and is accompanied 
by weight loss; this often being quite appreciable. In clini-
cal practice, weight loss will occur anyway when patients 
cannot orally consume food for more than a week or when 
energy needs are met in less than 60% of required levels for 
more than 1–2 weeks [4, 5].
A study by Martin et al on 11,000 patients with advanced 
malignancy confirmed that weight loss linked to a low BMI 
is an independent factor for overall survival (OS) [6]. Current 
recommendations define a nutrition high risk group (Tab. I), 
where the risk of complications associated with malnutrition 
is greatest [7, 8].
Recommendations
At present, a combination of therapeutic methods used 
affords the greatest opportunities, after appropriate qualifi-
cation for treatment, with the simultaneous use of suppor-
ting therapy. In Poland, recommendations for nutritional 
treatment in oncology were published in 2015 [9]. Such nu-
tritional intervention was recommended whenever clinically 
indicated (Tab. II) and at any step of oncological treatment.
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Perioperative feeding
The adverse impact of malnutrition on deteriorating 
outcomes following surgery has been well recognized in the 
literature since the 1970s and is still present today.
Initial reporting of nutritional intervention based on 
parenteral nutrition demonstrated, among other things, 
a reduced complication risk, especially sepsis, shortened 
hospital stays [10,11], and even reduced mortality for sur-
gical patients [12]. In view of the complications associated 
with supplying nutrients by this route, recommendations 
published in 2006 and in 2009 by the European Society for 
Clinical Nutrition and Metabolism (ESPEN) advise an enteral 
route [13], and if proving unfeasible, then a parenteral means 
be used (Fig. 1) [14, 15].
In those patients without malnutrition symptoms, 
any preoperative starvation should be avoided, as being 
part of perioperative care, and 60% of the body’s energy 
requirements should be met as soon as possible accord-
ing to the principles of ERAS (Enhanced Recovery After 
Surgery) [7–9]. 
Nutrition therapy in systemic treatment
During systemic treatment there are no indications for 
routinely using enteral or parenteral nutrition. An indica-
tion for intervention would be weight loss or its likely risk, 
especially in cases of advanced cancer disease [8]. However, 
nutritional therapy has a significant role in patients under-
going bone marrow transplantation, where high-dose my-
eloablative chemotherapy is used. Almost all patients reach 
enteropathy, and introducing nutritional therapy early on 
allows the patient to complete their treatment and influence 
outcomes [16].
Nutritional treatment in radiotherapy
Weight loss is very common upon using radiotherapy, 
particularly when combined with chemotherapy. This problem 
Table I. Severe nutritional risk — ESPEN Guidelines [7]
Weight loss > 10–15% within 6 months
BMI < 18.5 kg/m2
Subjective Global Assessment (SGA) Grade C or NRS > 5
Preoperative serum albumin < 30 g/L (with no evidence of hepatic or renal dysfunction)
Table II. Indications for nutritional intervention, Polish recommendations [9]
Inability of adopting an oral diet for more than 7 days
Current or threatening malnutrition (BMI < 18.5 kg/m2)
Unintentional weight loss > 10–15% in 6 months before treatment
Inability to maintain a daily food intake > 60% of the recommended standard for more than 10 days
Stage B and C in the SGA scale or a score of ≥ 3 points in the NRS 2002 screening method
Figure 1. Methods of delivering nutrition interventions [15]
Nutrition intervention
Possibility of oral intake
Oral nutrition/industrial  
diets (ONS)
Effective alimentary canal
Enteral nutrition  
(artificial access)








very often concerns patients undergoing radio-chemotherapy 
due to head and neck cancers where nutritional intervention 
beneficially effects nutritional status and the quality of life [17]. 
Nutrition therapy, often in the form of parenteral nutrition, 
may also be an indispensable element in cases of irradiated 
intestinal inflammation, even lasting for many years [18].
Cachexia, sarcopenia
Cachexia is a multifactorial syndrome, characterized 
by significant losses in weight as well as in adipose and 
muscle tissues, and a generalized inflammatory reaction. 
A definition popularized by Fearon also includes precachexia 
with only a little weight loss and a developed cachexia, 
which leads to death in less than 3 months [19]. Cachexia 
is particularly common in oncological patients and can be 
accompanied by locally or locoregionally advanced can-
cers [20]. Its presence shortens survival, as is also in the case 
for advanced cancer [21].
Sarcopenia indicates among others a muscle mass de-
cline most commonly associated with age, which occurs 
secondary in patients with malignant tumors. Its presence 
has an adverse prognostic significance and increases the 
risk of postoperative complications, as well as the toxicity 
of chemotherapy and on mortality [22].
Oncological patients after treatment
Nutritional support in many cases is relevant to patients 
who have completed radical oncological treatment. It is often 
essential in those with complications such as: short bowel 
syndrome, conditions after esophageal or stomach resection. 
Cured patients are significantly more likely to suffer from 
other medical conditions, thereby leading to poor health and 
an impaired quality of life linked also to health [23].
Summarizing
In conclusion, weight loss, muscle mass reduction are ad-
verse prognostic factors in patients with cancer. Nutritional in-
tervention allows any complications to be prevented or treated 
during cancer therapy, thereby improving its effectiveness, 
reducing cost, improving the quality of life, and prolonging 
the survival of some patients. As a general aim it is necessary 
to obtain the best outcomes for any oncological treatment.
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